Acuta Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Acuta Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-27,500	Closed	-$4.34M	–	47
2024 Q2	$4.34M	Sell	27,500 -36,662	-57%	-$4.71M	3.66%	11
2024 Q1	$8.31M	Sell	64,162 -6,438	-9%	-$789K	5.4%	6
2023 Q4	$6.81M	Buy	70,600 +55,100	+355%	+$5.29M	3.83%	7
2023 Q3	$1.88M	Buy	+15,500	New	+$1.75M	1.26%	26
2023 Q2	–	Sell	-32,770	Closed	-$4.52M	–	41
2023 Q1	$4.52M	Sell	32,770 -34,730	-51%	-$4.51M	3.33%	12
2022 Q4	$8.75M	Buy	67,500 +26,000	+63%	+$3.01M	5.38%	6
2022 Q3	$4.59M	Buy	+41,500	New	+$4.18M	1.98%	18
2018 Q3	–	Sell	-60,000	Closed	-$7.93M	–	47
2018 Q2	$7.93M	Buy	+60,000	New	+$5.66M	1.41%	17
2016 Q4	–	Sell	-50,000	Closed	-$2.01M	–	64
2016 Q3	$3.07M	Sell	50,000 -80,000	-62%	-$2.42M	1.15%	27
2016 Q2	$2.48M	Buy	+130,000	New	+$2.41M	1.19%	24
2015 Q4	–	Sell	-31,744	Closed	-$1.03M	–	66
2015 Q3	$1.02M	Buy	+31,744	New	+$1.08M	0.59%	43

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acuta Capital Partners's SRPT Position: Q3 2024 in Review

Acuta Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 27,500 shares — an estimated $4.34M sold.

Acuta Capital Partners first reported a position in SRPT in Q3 2015 and held it in 11 quarters. The position peaked at $8.75M in Q4 2022. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Acuta Capital Partners reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
Acuta Capital Partners sold 27,500 Sarepta Therapeutics shares in Q3 2024, an estimated $4.34M.
Acuta Capital Partners first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 11 quarters.
Acuta Capital Partners's Sarepta Therapeutics position peaked at $8.75M in Q4 2022.
458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.